Clinical trials: Venous Thrombosis
Perioperative Bleeding, Venous Thrombosis
PeriOperative ISchemic Evaluation-3 Trial
This study is a multicentre, international, randomized controlled trial of tranexamic acid (TXA) versus placebo and, using a partial factorial design, of a perioperative hypotension-avoidance versus hypertension-avoidance…
- Conditions
- Perioperative Bleeding, Venous Thrombosis, Arterial Thrombosis
- Trial name
- POISE-3 (NCT03505723)
- Testing
- Tranexamic Acid, Perioperative hypotension-avoidance strategy, Perioperative hypertension-avoidance strategy
- Where
- 114 sites in United States, Australia and 21 more
- Volunteers
- 9,535 people, healthy volunteers welcome
- Sponsor
- Population Health Research Institute
Anticoagulation, Atrial Fibrillation
AntiCoagulation Tracking InterVention and Evaluation
Anticoagulants are a leading cause of acute injury from adverse drug events, leading to ~20,000 serious injuries reported to the Food and Drug Administration per year and more than 220,000 emergency department visits annually.
- Conditions
- Anticoagulation, Atrial Fibrillation, Atrial Flutter, Pulmonary Embolus/Emboli
- Trial name
- ACTIVE (NCT04059965)
- Testing
- Panel Management for Anticoagulation Therapy, Usual Care
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or…
- Conditions
- Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
- Trial name
- NCT01011374
- Testing
- ranibizumab (Lucentis)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Retina Associates of Cleveland, Inc
Ischemia, Retinal Vein Occlusion
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
The RAVE 2 trial is a phase I, open label, 12-month trial of intravitreal ranibizumab 2.0 mg in patients with ischemic CRVO who have been either previously treated with ranibizumab or treatment naïve.
- Conditions
- Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases
- Trial name
- RAVE2 (NCT01225146)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- David M. Brown, M.D.
Venous Thrombosis
Intimate Partner Violence as a Risk Factor for Venous Thromboembolism in Women
The frequency of violence against women, or intimate partner violence (IPV) is more and more underlined and recognized as a cofactor favoring certain somatic and psychic pathologies.
- Trial name
- WAST-VTE (NCT05890924)
- Testing
- WAST questionnaire
- Where
- France
- Volunteers
- 997 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Acute Lymphoblastic Leukemia, Post Thrombotic Syndrome
Post-thrombotic Syndrome After Deep Venous Thrombosis (DVT) in Patients Treated According to the NOPHO ALL2008 Protocol
Acute lymphoblastic leukemia (ALL) is the most common malignant disease in childhood. Today more than 90% of children and 75% of adults (18-45 years) survive ALL.
- Trial name
- NCT04825548
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Pulmonary Embolism, Venous Thromboembolism
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding
- Trial name
- NCT06194617
- Testing
- Direct oral anticoagulant
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Tumor Cells, Circulating, Venous Thrombosis
The Correlation Between Circulatory Tumor Cells and Venous Thrombosis
Research indicates a strong correlation between cancer and thrombosis, with approximately 20% of blood clots in the U.S. being cancer-related, according to CDC data.
- Trial name
- NCT06672250
- Testing
- CTCs/CTMs culture
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Neoplasms, Deep Vein Thrombosis
Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients
Study Plan: Adult cancer patients who have a low risk profile and present with DVT will receive dalteparin 200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
- Trial name
- NCT00041782
- Testing
- Dalteparin (Fragmin)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Pulmonary Embolism, Venous Thrombosis
Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.
Observational. Retrospective cohort.
- Conditions
- Pulmonary Embolism, Venous Thrombosis, Portal Thrombosis
- Trial name
- NCT02597218
- Where
- Argentina
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Factor V Leiden, Prothrombin G20210A
A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism
This is a first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled, single ascending and multiple dose study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of…
- Conditions
- Factor V Leiden, Prothrombin G20210A, Venous Thromboembolism (VTE)
- Trial name
- NCT07430397
- Testing
- CITY-FXI
- Where
- United Kingdom
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- City Therapeutics
Contraception, Female Contraception
A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control
The purpose of the study is to use data from a health care information database to assess the risk of venous thromboembolism (blood clots), myocardial infarction (heart attacks), and stroke among women using a transdermal…
- Trial name
- NCT00377988
- Testing
- Transdermal Contraceptive System, Norgestimate-containing oral contraceptives with EE
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Deep Vein Thrombosis
New Clinical Score for Deep Vein Thrombosis
A new Clinical Score (CS) to rule out Deep Vein Thrombosis (DVT) has to be derived and internally validated (with bootstrap method), from patients suspected of DVT in Italy.
- Trial name
- NCT05680636
- Testing
- temperature measurement
- Where
- Italy
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Accademia Italiana Medicina Osteopatica
Branch Retinal Vein Occlusion
Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion
Several studies have indicated a relation between the development of RVO and elevated intraocular pressure (IOP) and glaucoma [9].
- Trial name
- NCT06146309
- Testing
- aflibercept (2mg/0.05ml)
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Venous Thromboembolism, Pregnancy Related
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
The preferences of pregnant women for postpartum thromboprophylaxis are largely unknown. The aims of this transversal study are to elicit the preferences of pregnant/postpartum women about postpartum thromboprophylaxis in…
- Trial name
- PREFER-PP (NCT05897697)
- Testing
- Interview
- Where
- 2 sites in France, Switzerland
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Marc Blondon
Venous Thromboembolism
Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients
Hospital acquired thrombosis describes blood clots that form in the legs and lungs after someone is treated in hospital. Clots in the leg can cause swelling, pain and other problems.
- Trial name
- PETS (NCT05347550)
- Testing
- Graduated Compression Stockings - Thromboembolic deterrent stockings
- Where
- 9 sites in United Kingdom
- Volunteers
- 21,472 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism
Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered
The Brigham and Women's Hospital (BWH) Patient Safety Learning Laboratory (PSLL) focuses on developing health information technology (HIT) tools to engage patients, family, and professional care team members in reliable…
- Conditions
- Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism, Patient Fall, Catheter-Associated Infection
- Trial name
- PSLL (NCT02969343)
- Testing
- Patient Safety health information technology
- Where
- United States
- Volunteers
- 21,000 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Hepatocellular Carcinoma
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Hepatic resection is the most effective curative treatment for resectable HCC, whereas frequent recurrence usually impaired the efficacy of hepatic resection and contributed poor survivals.
- Trial name
- NCT03914352
- Testing
- PD-1 antibody, TACE
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cancer Hospital of Guangxi Medical University
Coronary Heart Disease, Type 2 Diabetes
Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi FinTerveys Study
P5.fi study - P4 together with a fifth 'P' and '.fi' for population health Finally Implemented in Finland - studies the value of returning genetic and metabolomic risk information in two diseases (coronary heart disease and type…
- Conditions
- Coronary Heart Disease, Type 2 Diabetes, Deep Vein Thrombosis
- Trial name
- P5 (NCT03650127)
- Where
- Finland
- Volunteers
- 3,449 people, healthy volunteers welcome
- Sponsor
- Markus Perola
Embolism, Atrial Fibrillation and Venous Thrombosis
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects
The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 10mg and rivaroxaban granule formulation 10mg, and to assess the safety and tolerability of rivaroxaban 10mg in healthy adult male…
- Trial name
- NCT02537405
- Testing
- Rivaroxaban (BAY 59-7939), Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer